Join
Live feed
·
PRReleasevia Quantisnow
uniQure N.V. logo

uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

ByQuantisnow·Wall Street's wire, on your screen.
QURE· uniQure N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track QURE (uniQure N.V.) and more on Quantisnow.